{
    "clinical_study": {
        "@rank": "159581", 
        "acronym": "COLLAG4", 
        "arm_group": {
            "arm_group_label": "heart failure with preserved ejection fraction", 
            "description": "- Inclusion Elevated BNP EF > 50%"
        }, 
        "biospec_descr": {
            "textblock": "Proteomics"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Assessment of cardiac fibrosis by echocardiography (Speckle tracking), IRM (late-enhancement\n      imaging), biology (markers of collagen turn-over) and proteomics"
        }, 
        "brief_title": "Collagen Markers in Heart Failure and Preserved Ejection Fraction", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Left-sided Congestive Heart Failure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Heart failure (HF) is a growing public health problem. While HF with deteriorated ejection\n      fraction has faced numbers of (non) pharmacological advances, HF with preserved ejection\n      fraction, which represents half of admission has today no efficient treatment.\n\n      Fibrosis is found in heart of patients with HF and preserved ejection fraction, is\n      reponsible for stiff heart and has link to the transition to compensated/decompaseted HF and\n      death.\n\n      The purpose of this work is to characterise myocardial fibrosis by any means to change the\n      prognosis of patients with HF and preserved ejection fraction\n\n      Main purpose:\n\n      Assessment of cardiac fibrosis by echocardiography (Speckle tracking), IRM (late-enhancement\n      imaging), biology (markers of collagen turn-over) and proteomics\n\n        -  Patients selection\n\n             1. - Inclusion Criteria: Male or female > 18 and < 85 years of age. Recent HF\n                decompensation (framingham criteria, ejection fraction > 50% with 72 hours after\n                admission and BNP > 100 ng/L or NT-proBNP > 300 ng/L), signed inform consent.\n\n             2. - exclusion criteria: hypertrophic cardiomyopathy, restrictive cardiomyopathy,\n                constrictive pericarditis, significant respiratory disease, pulmonary\n                hypertension, core pulmonale, end-stage kidney disease, high cardiac output HF,\n                isolated right ventricular dysfunction, pregnancy or child-bearing, biventricular\n                pacing, No health insurance.\n\n        -  Control group\n\n             1. - inclusion criteria: Male or female > 18 and < 85 years of age. signed inform\n                consent. Health insurance.\n\n             2. - exclusion criteria: significant ischemic heart disease, significant valvular\n                heart disease, pericarditis, pulmonary hypertension, hypertrophic cardiomyopathy,\n                restrictive cardiomyopathy, constrictive pericarditis, significant respiratory\n                disease, pulmonary hypertension, core pulmonale, end-stage kidney disease, high\n                cardiac output HF, isolated right ventricular dysfunction, pregnancy or\n                child-bearing, biventricular pacing, No health insurance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "- inclusion Signs of heart failure Elevated BNP EF > 50% within 72 hours after admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "heart failure with preserved ejection fraction"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2010", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677494", 
            "org_study_id": "2010/068/HP"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 29, 2012", 
        "location": {
            "contact": {
                "email": "fabrice.bauer@chu-rouen.fr", 
                "last_name": "Fabrice Bauer, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Rouen", 
                    "country": "France", 
                    "zip": "76031"
                }, 
                "name": "Rouen university hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "1", 
        "official_title": "To Assess the 12-month Prognostic Significance of Left Ventricular Collagen Markers in Patients With Heart Failure and Preserved Ejection Fraction.", 
        "overall_official": {
            "affiliation": "Rouen University Hospital", 
            "last_name": "Fabrice Bauer, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_outcome": {
            "measure": "death and admission for heart failure", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University Hospital, Rouen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Rouen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2012"
    }
}